Headquartered in Philadelphia, PA Fiscal year ends December NASDAQ: CABA cabalettabio.com
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company developing curative targeted cell therapies for patients with autoimmune diseases. Its lead product candidate, resecabtagene autoleucel (rese-cel), is an investigational 4-1BB-containing fully human CD19-CAR T cell therapy administered as a single, weight-based intravenous infusion designed to reset the immune system. Rese-cel is being advanced across the RESET (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas including rheumatology (myositis, systemic sclerosis, lupus), neurology (myasthenia gravis, multiple sclerosis), and dermatology (pemphigus vulgaris). The company is pursuing registrational trials in dermatomyositis/antisynthetase syndrome and SSc-associated interstitial lung disease, with a first BLA submission targeted for 2H 2027. Cabaletta is also developing a preconditioning-free dosing approach and outpatient administration model. Manufacturing is supported through partnerships with Lonza, ElevateBio, and Cellares for automated commercial-scale production. The company is pre-revenue and generates no product sales. Updated
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company developing curative targeted cell therapies for patients with autoimmune diseases.
The Wall Street consensus 12-month price target for CABA is $13.25.
